• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

归因于 COVID-19 感染的头痛特征及其频率和强度的预测因素:一项横断面研究。

Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study.

机构信息

Department of Neurology, Cairo University, Cairo, Egypt.

Department of Neurology, Beni-Suef University, Beni-Suef, Egypt.

出版信息

Cephalalgia. 2020 Nov;40(13):1422-1431. doi: 10.1177/0333102420965140.

DOI:10.1177/0333102420965140
PMID:33146038
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7645600/
Abstract

OBJECTIVE

To study the characteristics of headache attributed to COVID-19 infection and predictors of its severity.

METHODS

A cross-sectional study involved 172 individuals who had headache due to COVID-19 infection. A detailed analysis of such headache was done through a face-to-face interview. Patients with any other form of secondary headache were excluded. Labs, including lymphocytic count, C-reactive protein, D-dimer and ferritin and chest imaging, were made available.

RESULTS

THE: majority of our patients had a diffuse headache (52.9%). It was pressing in 40.7%, with median intensity of 7 (assessed by visual analogue scale) and median frequency of 7 days/week. Patients with preexisting primary headache (52.9%) had significantly more frequent COVID-19 related headache than those without (47.1%) ( = 0.001). Dehydrated patients (64.5%) had more frequent COVID-19 related headache than those who were not dehydrated (35.5%) ( = 0.029). Patients with fever (69.8%) had significantly higher frequency and intensity of COVID-19 related headache compared to those without fever (30.2%) ( = 0.003, 0.012). Patients with comorbidities (19.8%) had significantly higher frequency and intensity of headache than those without comorbidities (80.2%) ( = 0.006, 0.003). After multiple linear regression, primary headache disorders, dehydration and comorbidities were considered predictors of frequency of COVID-19 related headache. Meanwhile, fever and dehydration were predictors of pain intensity.

CONCLUSION

Healthcare providers of COVID-19 patients need to be aware of frequency and intensity predictors of COVID-19 related headache: Primary headache disorders, fever, dehydration, and comorbidities.

摘要

目的

研究与 COVID-19 感染相关的头痛的特征和严重程度的预测因素。

方法

本横断面研究纳入了 172 名因 COVID-19 感染而出现头痛的患者。通过面对面访谈对这种头痛进行了详细分析。排除了任何其他形式的继发性头痛的患者。提供了实验室检查,包括淋巴细胞计数、C 反应蛋白、D-二聚体和铁蛋白以及胸部影像学检查。

结果

我们的大多数患者(52.9%)患有弥漫性头痛。其中 40.7%为压迫性头痛,视觉模拟评分中位数为 7,中位数频率为每周 7 天。有原发性头痛病史的患者(52.9%)比无原发性头痛病史的患者(47.1%)发生 COVID-19 相关头痛的频率更高( = 0.001)。脱水患者(64.5%)发生 COVID-19 相关头痛的频率高于未脱水患者(35.5%)( = 0.029)。发热患者(69.8%)发生 COVID-19 相关头痛的频率和强度明显高于无发热患者(30.2%)( = 0.003,0.012)。合并症患者(19.8%)发生头痛的频率和强度明显高于无合并症患者(80.2%)( = 0.006,0.003)。经多元线性回归分析,原发性头痛障碍、脱水和合并症被认为是 COVID-19 相关头痛频率的预测因素。同时,发热和脱水是疼痛强度的预测因素。

结论

COVID-19 患者的医护人员需要了解 COVID-19 相关头痛的频率和强度预测因素:原发性头痛障碍、发热、脱水和合并症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba6a/7645600/d7fb469a40fd/10.1177_0333102420965140-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba6a/7645600/1d696f41e995/10.1177_0333102420965140-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba6a/7645600/d7fb469a40fd/10.1177_0333102420965140-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba6a/7645600/1d696f41e995/10.1177_0333102420965140-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba6a/7645600/d7fb469a40fd/10.1177_0333102420965140-fig2.jpg

相似文献

1
Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study.归因于 COVID-19 感染的头痛特征及其频率和强度的预测因素:一项横断面研究。
Cephalalgia. 2020 Nov;40(13):1422-1431. doi: 10.1177/0333102420965140.
2
Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients.急性头痛的表型特征归因于 SARS-CoV-2:一项对 106 例住院患者的 ICHD-3 验证研究。
Cephalalgia. 2020 Nov;40(13):1432-1442. doi: 10.1177/0333102420965146.
3
Association between COVID-19 and headache: What evidence and history tell us.新型冠状病毒肺炎与头痛之间的关联:证据和历史告诉我们什么。
Cephalalgia. 2020 Nov;40(13):1403-1405. doi: 10.1177/0333102420965969.
4
Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia.与 COVID-19 相关的头痛:频率、特征以及与嗅觉丧失和味觉丧失的关联。
Cephalalgia. 2020 Nov;40(13):1443-1451. doi: 10.1177/0333102420966770.
5
Isolated intracranial hypertension associated with COVID-19.与 COVID-19 相关的孤立性颅内压增高。
Cephalalgia. 2020 Nov;40(13):1452-1458. doi: 10.1177/0333102420965963.
6
Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: Lessons from the 1890 Russian/Asiatic flu.在全球大流行期间,病毒性疾病后出现每日持续性头痛可能并非新现象:1890 年俄罗斯/亚洲流感的教训。
Cephalalgia. 2020 Nov;40(13):1406-1409. doi: 10.1177/0333102420965132.
7
Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross-Sectional Study.头痛为 2019 冠状病毒病的主要症状:一项横断面研究。
Headache. 2020 Nov;60(10):2176-2191. doi: 10.1111/head.13967. Epub 2020 Sep 28.
8
Smell and Taste Dysfunction in COVID-19 Is Associated With Younger Age in Ambulatory Settings: A Multicenter Cross-Sectional Study.在门诊环境中,COVID-19 嗅觉和味觉障碍与年龄较小有关:一项多中心横断面研究。
J Investig Allergol Clin Immunol. 2020;30(5):346-357. doi: 10.18176/jiaci.0595. Epub 2020 Jun 17.
9
Relative Frequency and Risk Factors of COVID-19 Related Headache in a Sample of Egyptian Population: A Hospital-Based Study.埃及人群中 COVID-19 相关头痛的相对频率和危险因素:一项基于医院的研究。
Pain Med. 2021 Sep 8;22(9):2092-2099. doi: 10.1093/pm/pnab020.
10
Neurological manifestations of COVID-19.新型冠状病毒肺炎的神经学表现
J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S101-S103. doi: 10.5455/JPMA.20.

引用本文的文献

1
Long-Term Persistent Headache After SARS-CoV-2 Infection: A Follow-Up Population-Based Study.新型冠状病毒感染后的长期持续性头痛:一项基于人群的随访研究。
Eur J Neurol. 2025 May;32(5):e70130. doi: 10.1111/ene.70130.
2
Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used.根据所使用疫苗区分的新冠疫苗接种后头痛的表型比较。
Vaccines (Basel). 2025 Jan 23;13(2):113. doi: 10.3390/vaccines13020113.
3
Migraine symptoms and association of triggers, coping strategies and clinical characteristics with COVID-19 diagnosis among university students in Peninsular Malaysia: A cross-sectional study.

本文引用的文献

1
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴:目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
2
The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries.24410 名新型冠状病毒(SARS-CoV-2;COVID-19)感染者的症状流行率:来自 9 个国家的 148 项研究的系统评价和荟萃分析。
PLoS One. 2020 Jun 23;15(6):e0234765. doi: 10.1371/journal.pone.0234765. eCollection 2020.
3
COVID-19 and the nervous system.
马来西亚半岛大学生中偏头痛症状、触发因素、应对策略及临床特征与新冠病毒病诊断的关联:一项横断面研究
Malays Fam Physician. 2024 Jul 31;19:43. doi: 10.51866/oa.521. eCollection 2024.
4
Post-COVID-19 headache- NDPH phenotype: a systematic review of case reports.新冠后头痛——新发性每日持续性头痛表型:病例报告的系统评价
Front Pain Res (Lausanne). 2024 May 14;5:1376506. doi: 10.3389/fpain.2024.1376506. eCollection 2024.
5
Clinical presentation of post-COVID pain and its impact on quality of life in long COVID patients: a cross-sectional household survey of SARS-CoV-2 cases in Bangladesh.孟加拉国 SARS-CoV-2 病例的横断面家庭调查:COVID 后疼痛的临床表现及其对长期 COVID 患者生活质量的影响。
BMC Infect Dis. 2024 Apr 4;24(1):375. doi: 10.1186/s12879-024-09267-3.
6
Headaches and facial pain attributed to SARS-CoV-2 infection and vaccination: a systematic review.与 SARS-CoV-2 感染和疫苗接种相关的头痛和面部疼痛:系统评价。
Eur J Neurol. 2024 Jun;31(6):e16251. doi: 10.1111/ene.16251. Epub 2024 Feb 28.
7
NEURO-COVAX: An Italian Population-Based Study of Neurological Complications after COVID-19 Vaccinations.NEURO-COVAX:一项基于意大利人群的新冠疫苗接种后神经系统并发症研究。
Vaccines (Basel). 2023 Oct 21;11(10):1621. doi: 10.3390/vaccines11101621.
8
Characteristics of headaches attributed to SARS-CoV-2 vaccination and factors associated with its frequency and prolongation: a cross-sectional cohort study.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)疫苗接种所致头痛的特征及其频率和持续时间相关因素:一项横断面队列研究
Front Neurol. 2023 Aug 2;14:1214501. doi: 10.3389/fneur.2023.1214501. eCollection 2023.
9
Unusual Presentation of COVID-19 Headache and Its Possible Pathomechanism.新型冠状病毒肺炎头痛的不寻常表现及其可能的发病机制
Cureus. 2022 Sep 20;14(9):e29358. doi: 10.7759/cureus.29358. eCollection 2022 Sep.
10
Post-COVID Headache: A Literature Review.新冠后头痛:文献综述。
Curr Pain Headache Rep. 2022 Nov;26(11):835-842. doi: 10.1007/s11916-022-01086-y. Epub 2022 Oct 5.
新型冠状病毒肺炎与神经系统。
J Neurovirol. 2020 Apr;26(2):143-148. doi: 10.1007/s13365-020-00840-5. Epub 2020 May 23.
4
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.中国武汉住院的 2019 年冠状病毒病患者的神经系统表现。
JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127.
5
Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis.人类新型冠状病毒感染(COVID-19):一项范围综述与荟萃分析
J Clin Med. 2020 Mar 30;9(4):941. doi: 10.3390/jcm9040941.
6
Care for Critically Ill Patients With COVID-19.对新冠肺炎危重症患者的护理
JAMA. 2020 Apr 21;323(15):1499-1500. doi: 10.1001/jama.2020.3633.
7
The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.新型冠状病毒肺炎(COVID-19)的潜伏期来自公开报告的确诊病例:估计和应用。
Ann Intern Med. 2020 May 5;172(9):577-582. doi: 10.7326/M20-0504. Epub 2020 Mar 10.
8
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.严重急性呼吸综合征相关冠状病毒:将 2019-nCoV 进行分类并命名为 SARS-CoV-2。
Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2.
9
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
10
Coronavirus in China.中国的冠状病毒。
Lancet Respir Med. 2020 Mar;8(3):238. doi: 10.1016/S2213-2600(20)30056-4. Epub 2020 Feb 3.